Goldman Sachs Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $74
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter has initiated coverage on Apellis Pharmaceuticals with a Buy rating and a price target of $74.
November 09, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Apellis Pharmaceuticals with a Buy rating and a price target of $74, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. A Buy rating from a reputable institution like Goldman Sachs indicates a positive outlook for the stock. The price target of $74 also suggests a potential upside, which could attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100